JP2003504061A - プラスミド配列の転写の間における異常型rnaの形成を防止するための方法および組成物 - Google Patents
プラスミド配列の転写の間における異常型rnaの形成を防止するための方法および組成物Info
- Publication number
- JP2003504061A JP2003504061A JP2001509517A JP2001509517A JP2003504061A JP 2003504061 A JP2003504061 A JP 2003504061A JP 2001509517 A JP2001509517 A JP 2001509517A JP 2001509517 A JP2001509517 A JP 2001509517A JP 2003504061 A JP2003504061 A JP 2003504061A
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- strand
- polynucleotide
- terminator
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14305999P | 1999-07-09 | 1999-07-09 | |
US60/143,059 | 1999-07-09 | ||
PCT/US2000/017670 WO2001004313A1 (en) | 1999-07-09 | 2000-06-27 | Methods and compositions for preventing the formation of aberrant rna during transcription of a plasmid sequence |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2003504061A true JP2003504061A (ja) | 2003-02-04 |
Family
ID=22502421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001509517A Pending JP2003504061A (ja) | 1999-07-09 | 2000-06-27 | プラスミド配列の転写の間における異常型rnaの形成を防止するための方法および組成物 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1194556A1 (ko) |
JP (1) | JP2003504061A (ko) |
KR (1) | KR20020030780A (ko) |
CN (1) | CN1360631A (ko) |
AU (1) | AU783681B2 (ko) |
BR (1) | BR0012325A (ko) |
CA (1) | CA2378653A1 (ko) |
IL (1) | IL147026A0 (ko) |
MX (1) | MXPA01013462A (ko) |
WO (1) | WO2001004313A1 (ko) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
HU230353B1 (hu) | 1998-03-20 | 2016-02-29 | Benitec Australia Ltd | A génexpresszió szabályozása |
EP1147204A1 (en) | 1999-01-28 | 2001-10-24 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
US7601494B2 (en) | 1999-03-17 | 2009-10-13 | The University Of North Carolina At Chapel Hill | Method of screening candidate compounds for susceptibility to biliary excretion |
US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
WO2001068835A2 (en) * | 2000-03-13 | 2001-09-20 | Aptagen | Method for modifying a nucleic acid |
US20020132257A1 (en) | 2001-01-31 | 2002-09-19 | Tony Giordano | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
WO2002077609A2 (en) | 2001-03-26 | 2002-10-03 | Message Pharmaceuticals, Inc. | Identification of compounds for the treatment or prevention of proliferative diseases |
US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
EP1800697B1 (de) | 2001-06-05 | 2010-04-14 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt für die Gentherapie |
US7897382B2 (en) | 2001-10-22 | 2011-03-01 | Alnylam Pharmaceuticals, Inc. | Transfection kinetics and structural promoters |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
EP1432724A4 (en) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA inhibition mediated inhibition of MAP KINASE GENES |
US20040180438A1 (en) | 2002-04-26 | 2004-09-16 | Pachuk Catherine J. | Methods and compositions for silencing genes without inducing toxicity |
DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
EP1623009A4 (en) * | 2003-04-22 | 2008-02-13 | Nucleonics Inc | TRANSFECTION KINETICS AND STRUCTURAL PROMOTERS |
AU2005212433B2 (en) | 2003-05-23 | 2010-12-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sINA) |
WO2005078848A2 (en) | 2004-02-11 | 2005-08-25 | University Of Tennessee Research Foundation | Inhibition of tumor growth and invasion by anti-matrix metalloproteinase dnazymes |
CA2559955C (en) | 2004-03-15 | 2016-02-16 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
AU2005238034A1 (en) | 2004-04-23 | 2005-11-10 | The Trustees Of Columbia University In The City Of New York | Inhibition of hairless protein mRNA |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
EP1782321A4 (en) | 2004-07-23 | 2009-11-04 | Univ North Carolina | METHOD AND MATERIALS FOR DETERMINING PAIN SENSITIVITY AND PREDICTING AND TREATING SUFFERING INTERFERENCE |
WO2007011702A2 (en) | 2005-07-15 | 2007-01-25 | The University Of North Carolina At Chapel Hill | Use of egfr inhibitors to prevent or treat obesity |
EP1931789B1 (en) | 2005-09-20 | 2016-05-04 | BASF Plant Science GmbH | Methods for controlling gene expression using ta-siran |
AU2008207735B2 (en) | 2007-01-26 | 2013-10-03 | University Of Louisville Research Foundation, Inc. | Modification of exosomal components for use as a vaccine |
US8796442B2 (en) | 2007-03-21 | 2014-08-05 | Brookhaven Science Associates, Llc. | Combined hairpin-antisense compositions and methods for modulating expression |
EP3000885B1 (en) | 2009-12-18 | 2018-07-25 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat hsf1-related diseases |
WO2011098449A1 (en) | 2010-02-10 | 2011-08-18 | Novartis Ag | Methods and compounds for muscle growth |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
CA3162352A1 (en) | 2010-10-01 | 2012-04-05 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
LT2791160T (lt) | 2011-12-16 | 2022-06-10 | Modernatx, Inc. | Modifikuotos mrnr sudėtys |
EP2802658A2 (en) | 2012-01-09 | 2014-11-19 | Novartis AG | Rnai agents to treat beta-catenin related diseases |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
CA2868996A1 (en) | 2012-04-02 | 2013-10-10 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
EP3423568A4 (en) | 2016-03-04 | 2019-11-13 | University Of Louisville Research Foundation, Inc. | METHOD AND COMPOSITIONS FOR EX-VIVO REPRODUCTION OF VERY SMALL EMBRYONAL STEM CELLS (VSELS) |
US20200362345A1 (en) * | 2019-05-17 | 2020-11-19 | Massachusetts Institute Of Technology | Engineered post-poly a signal rna and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5587300A (en) * | 1994-04-26 | 1996-12-24 | Wisconsin Ulumni Research Foundation | Method to increase regulatory molecule production |
US5888774A (en) * | 1994-12-19 | 1999-03-30 | Cangene Corporation | Recombinant DNA molecules and expression vectors for erythropoietin |
US6022863A (en) * | 1996-05-21 | 2000-02-08 | Yale University | Regulation of gene expression |
AU8916098A (en) * | 1997-08-22 | 1999-03-16 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Polynucleotide inhibition of rna destabilization and sequestration |
EP1021549A2 (en) * | 1997-09-19 | 2000-07-26 | Sequitur, Inc. | SENSE mRNA THERAPY |
-
2000
- 2000-06-27 EP EP00944916A patent/EP1194556A1/en not_active Withdrawn
- 2000-06-27 AU AU58937/00A patent/AU783681B2/en not_active Ceased
- 2000-06-27 JP JP2001509517A patent/JP2003504061A/ja active Pending
- 2000-06-27 BR BR0012325-0A patent/BR0012325A/pt not_active IP Right Cessation
- 2000-06-27 MX MXPA01013462A patent/MXPA01013462A/es unknown
- 2000-06-27 KR KR1020027000339A patent/KR20020030780A/ko not_active Application Discontinuation
- 2000-06-27 WO PCT/US2000/017670 patent/WO2001004313A1/en not_active Application Discontinuation
- 2000-06-27 CA CA002378653A patent/CA2378653A1/en not_active Abandoned
- 2000-06-27 CN CN00810072A patent/CN1360631A/zh active Pending
- 2000-06-27 IL IL14702600A patent/IL147026A0/xx unknown
Also Published As
Publication number | Publication date |
---|---|
IL147026A0 (en) | 2002-08-14 |
CN1360631A (zh) | 2002-07-24 |
WO2001004313A1 (en) | 2001-01-18 |
MXPA01013462A (es) | 2002-07-02 |
AU783681B2 (en) | 2005-11-24 |
CA2378653A1 (en) | 2001-01-18 |
BR0012325A (pt) | 2002-05-21 |
AU5893700A (en) | 2001-01-30 |
EP1194556A1 (en) | 2002-04-10 |
KR20020030780A (ko) | 2002-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2003504061A (ja) | プラスミド配列の転写の間における異常型rnaの形成を防止するための方法および組成物 | |
KR102580696B1 (ko) | 신규 인공 핵산 분자 | |
EP3684925B1 (en) | Non-integrating dna vectors for the genetic modification of cells | |
EP2305699B1 (de) | Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Impfung gegen Schlafkrankheit, Leishmaniose und Toxoplasmose | |
KR20180117171A (ko) | 비-바이러스 유전자 전달을 위한 폐쇄형-말단 선형 듀플렉스 dna | |
US20040002077A1 (en) | siRNA expression system and method for producing functional gene knock-down cell using the system | |
EP1462525B1 (en) | siRNA EXPRESSION SYSTEM AND PROCESS FOR PRODUCING FUNCTIONAL GENE KNOCKDOWN CELL OR THE LIKE USING THE SAME | |
US20210010021A1 (en) | Viral and non-viral nanoplasmid vectors with improved production | |
JPH11511009A (ja) | 細胞への核酸運搬のためのプラスミドおよび使用方法 | |
JP6918231B2 (ja) | 遺伝子治療DNAベクターVTvaf17と生産方法;大腸菌株SCS110−AFと生産方法;遺伝子治療DNAベクターVTvaf17を保持する大腸菌株SCS110−AF/VTvaf17と生産方法 | |
KR930703453A (ko) | 유전자 치료법을 위한 안전한 벡터 | |
US20230279407A1 (en) | Recombinant nucleic acid molecule based on point mutation of translation initiation element and use thereof in preparation of circular rna | |
KR20200036025A (ko) | 메신저 리보핵산(mRNA)을 암호화하는 안정화된 핵산 | |
CN112662674A (zh) | 靶向编辑VEGFA基因外显子区域的gRNA及其应用 | |
JP2011500080A (ja) | 癌治療用の多数の発現カセットを含む構造体 | |
KR101442254B1 (ko) | 최적의 진핵 세포 발현 벡터의 개발 | |
US20060171924A1 (en) | Bidirectional promoters for small RNA expression | |
US20020086427A1 (en) | Inducible eukaryotic expression system that regulates protein translation | |
JP4774493B2 (ja) | 哺乳動物遺伝子発現を調節するための分子スイッチ | |
KR20220049619A (ko) | 유전자 발현 조절 시스템 | |
JP4491808B1 (ja) | 高発現細胞の効率的な選別に有用な薬剤選択マーカー遺伝子発現カセット | |
JP2002519059A (ja) | ミオスタチン遺伝子の新規なプロモーター配列 | |
CN114908089B (zh) | 3’utr的构建方法和应用 | |
KR102590276B1 (ko) | 조직 특이적 발현을 위한 융합 프로모터 및 이의 용도 | |
JP2010521460A (ja) | 癌免疫療法におけるIi−RNAi関与Ii抑制 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060822 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070130 |